Arca
Skip to content
Tools
Tools

Hunter syndrome

Drug research and approvals for hunter syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 7 studies of hunter syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 2 approved and 5 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 7
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 2
  • EU medicines: 1

Recruiting now

Newest posted first, of 7 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

Newest first; search them all in Canada trials
Dec 15, 2023An open-label extension for subjects in studies HGT-HIT-046 and SHP609-302 evaluating long-term safety of intrathecal idursulfase-it administered in…Idursulfase-it (HGT-2310)Takeda Pharmaceuticals USAOngoing
Oct 26, 2022A phase 1/2/3 multicenter, open label study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of RGX-121 in pediatric subjects with mps ii…RGX-121 / Rapamune / Prograf / Prednisolone / MedrolREGENXBIOClosed
Aug 12, 2021A phase 1/2, multicenter, open-label study to determine the safety, pharmacokinetics, and pharmacodynamics of DNL310 in pediatric subjects with hunter syndromeDNL310Denali TherapeuticsClosed
Apr 24, 2015"an open label extension of study HGT-HIT-094 evaluating long term safety and clinical outcomes of intrathecal idursulfase administered in conjunction with…HGT-2310 (idursulfast-it)Takeda Pharmaceuticals USAOngoing
Mar 25, 2014A controlled, randomized, two-arm, open-label, assessor-blinded, multicenter study of intrathecal idursulfase-ot administered in conjunction with elaprase in…HGT-2310; idursulfase-itTakeda Pharmaceuticals USAOngoing

FDA orphan designations

Approved first, then open designations, newest first
Mar 24, 2026AvlayahTreatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or…Denali Therapeutics Inc.Approved
Jul 24, 2006ElapraseIndicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in…Takeda Pharmaceuticals U.S.A., Inc.Approved
Mar 28, 2023Adeno-associated virus vector expressing human…Treatment of mucopolysaccharidosis (MPS) II, also called Hunter syndromeNeuroGT, Inc.Designated
Oct 15, 2018Humanized IgG-1 antibody targeting human transferrin…Treatment of Mucopolysaccharidosis Type II (MPS II) or Hunter SyndromeJCR Pharmaceuticals Co., Ltd.Designated
Sep 1, 2016Recombinant adeno-associated virus vector serotype 9…Treatment of mucopolysaccharidosis II, also called Hunter syndrome A.University of North Carolina at Chapel HillDesignated
May 15, 2013HIRMAb-IDSTreatment of mucopolysaccharidosis Type II (Hunter Syndrome)ArmaGen Technologies, Inc.Designated
Feb 11, 2013Idursulfase betaTreatment of Hunter Syndrome (mucopolysaccharidoses)Green Cross Corp.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Jan 8, 2007ElapraseIdursulfaseTakeda Pharmaceuticals International AG Ireland BranchEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.